Home / Health / Patient's Journey Fuels Ovarian Cancer Breakthrough
Patient's Journey Fuels Ovarian Cancer Breakthrough
11 May
Summary
- Ovarian cancer research at Dalhousie University is advancing.
- Natural killer cells are being studied for immunotherapy treatment.
- The research received $725,000 in funding from Ovarian Cancer Canada.
Teresa Arthur's diagnosis of Stage 4 ovarian cancer in July 2018 has inspired groundbreaking research at Dalhousie University. Arthur, a retired chemistry teacher, is collaborating with immunologist Jeanette Boudreau's lab, which focuses on utilizing the patient's own immune system through natural killer (NK) cell immunotherapy.
This innovative approach aims to combat ovarian cancer's tendency to mutate by enhancing the patient's NK cells. The lab has developed methods to obtain NK cells from donated white blood cells, minimizing potential side effects associated with other immunotherapies. The research received a significant boost of $725,000 in funding from Ovarian Cancer Canada, a vital step towards future clinical trials.
The lab is equipped with advanced technology, including a new machine named ThiNKer, which aids in the mass production of NK cells. By studying actual patient tumors, the researchers can test various therapies and provide valuable insights for patient care conversations. Arthur's involvement highlights the importance of patient perspectives in understanding and developing effective treatments for ovarian cancer.
